A medicament for the therapeutic treatment of diabetes which comprises as an active ingredient a compound represented by the general formula (I):
wherein R1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R2 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R3 represents a hydrogen atom, a lower alkyl group or a substituted or unsubstituted aralkyl group, X1 and X2 independently represent a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and the symbol "n" represents an integer of from 0 to 3, or a physiologically acceptable salt thereof.
Exploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement
作者:Linda S. Barton、James F. Callahan、Juan Cantizani、Nestor O. Concha、Ignacio Cotillo Torrejon、Nicole C. Goodwin、Amruta Joshi-Pangu、Terry J. Kiesow、Jeff J. McAtee、Mark Mellinger、Christopher J. Nixon、Laura Padrón-Barthe、Jaclyn R. Patterson、Neil D. Pearson、Jeffrey J. Pouliot、Alan R. Rendina、Alexander Buitrago Santanilla、Jessica L. Schneck、Olalla Sanz、Reema K. Thalji、Paris Ward、Shawn P. Williams、Bryan W. King